STOCKWATCH
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Quarterly ResultApr 28, 2026, 04:09 PM

AXGN Q1 Net Loss $(19.6)M; $133.3M Stock Offering & Debt Repayment

AI Summary

Axogen, Inc. reported a net loss of $(19.6) million for Q1 2026, primarily driven by a $16.8 million loss on extinguishment of debt. This debt repayment of $69.7 million was funded by net proceeds of $133.3 million from a public offering of common stock. The company also saw a 26.6% increase in revenues to $61.5 million and a significant improvement in cash flow from operations.

Key Highlights

  • Completed public offering of 4.6M shares, raising $133.3M net proceeds.
  • Repaid Credit Facility debt of $69.7M, terminating the agreement.
  • Recorded a $16.8M loss on extinguishment of debt in Q1 2026.
  • Q1 2026 revenues increased 26.6% to $61.5M from $48.6M YoY.
  • Q1 2026 net loss was $(19.6)M, compared to $(3.8)M in Q1 2025.
  • Q1 2026 basic net loss per share was $(0.38) vs. $(0.08) YoY.
  • Net cash provided by operating activities was $1.6M, up from $(13.2)M used YoY.
  • Cash and cash equivalents, and restricted cash, ended at $84.7M.
AXGN
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Axogen, Inc.

Price Impact